Inactivated Vaccines Market Forecast for Expansion to US$34.26 Billion by 2033, Powered by Pediatric/Adult Vaccination Coverage and Pandemic Preparedness | Key Players -GSK plc., Sanofi., Biological E Limited.

The Global Inactivated Vaccines Market reached US$22.60 billion in 2024 and is expected to reach US$34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032.The inactivated vaccines market is growing due to rising immunization programs, increasing prevalence of infectious diseases, expanding pediatric and adult vaccination coverage, government funding initiatives, and advancements in vaccine manufacturing technologies. Strong safety profiles and global pandemic preparedness efforts further support sustained market demand.

📌 Download your Sample Report Instantly - Corporate Email ID required for priority access:-https://www.datamintelligence.com/download-sample/inactivated-vaccines-market?prtk

Key Development 2026-

✅ December 2025: Sanofi Pasteur expanded its inactivated polio vaccine production facility in Pennsylvania, increasing output by 25% to address global supply shortages amid rising immunization campaigns.

✅ October 2025: GSK received FDA approval for an enhanced inactivated influenza vaccine with broader strain coverage, targeting high-risk elderly populations and reducing hospitalization rates by 15%.

✅ August 2025: Merck & Co. launched a next-generation inactivated hepatitis A vaccine with improved thermostability, facilitating distribution in remote U.S. areas and boosting vaccination rates.

✅ November 2025: The Japanese Ministry of Health approved subsidies for inactivated Japanese encephalitis vaccines, promoting uptake in rural areas with enhanced local manufacturing partnerships.

✅ September 2025: KM Biologics introduced an upgraded inactivated rabies vaccine with faster immune response, approved by PMDA for post-exposure prophylaxis in high-risk travelers and professionals

✅ July 2025: Denka collaborated on a novel inactivated pertussis combination vaccine, integrating advanced adjuvants to improve efficacy against evolving strains in pediatric immunization programs.

Recent M&A Activity-

✅ Sanofi acquires ViceBio Ltd. - Sanofi expanded its global vaccine capabilities by acquiring UK-based ViceBio, a clinical-stage biotech focused on next-generation respiratory vaccines, in a deal valued at up to US$1.6 billion (upfront US$1.15B plus potential milestones). This acquisition enhances Sanofi's pipeline in combination vaccines for RSV and human metapneumovirus. Date: Completed December 4, 2025.

✅ BioNTech acquires CureVac N.V. - German biotech BioNTech completed the acquisition of rival CureVac for approximately US$1.25 billion in equity value. The deal brings CureVac's portfolio of clinical-stage mRNA vaccines into BioNTech's pipeline, supporting broader vaccine and immunotherapy development. Date: Closed December 18, 2025.

✅ Sanofi to acquire Dynavax Technologies - Sanofi agreed to acquire US-based Dynavax Technologies for about US$2.2 billion in cash, strengthening its adult vaccine portfolio with the marketed hepatitis B vaccine HEPLISAV-B and an early-stage shingles candidate. The announcement was made late December 2025 with expected closing in early 2026.

Market segmentation-

The inactivated vaccines market exhibits structured segmentation across key dimensions, reflecting diverse product formulations, usage contexts, and regional dynamics that drive global demand for safe, stable immunization solutions. By Type, the market primarily divides into viral vaccines (e.g., polio, hepatitis A, influenza), bacterial vaccines (e.g., typhoid, cholera), and others like toxoids (tetanus, diphtheria); viral types lead due to high-volume demand from endemic diseases and routine programs, fueled by regulatory approvals and booster needs, underscoring their significance in preventing widespread outbreaks and reducing healthcare burdens. Component segmentation, often encompassing whole virus inactivated, split/subunit, and toxoid variants, highlights subunit vaccines' growth from enhanced safety profiles and tolerability, driven by adult immunization trends and combination shots that improve compliance and market penetration.

Deployment models focus on production methods like solvent-detergent inactivation, heat, radiation, or pH concentration, with heat and chemical methods dominating for scalability and cost-effectiveness; these enable broad deployment in mass campaigns, propelled by technological advances in stability for emerging pathogens, amplifying market significance through reliable supply chains amid pandemics. Application-wise, segments include indications such as polio, rabies, influenza, hepatitis A, and combination vaccines, where influenza and rabies drive expansion via seasonal and travel-related uptake, supported by rising infectious disease incidence and WHO eradication goals that boost preventive healthcare investments.

End-User categories span public health programs, hospitals, pediatric clinics, specialty/travel clinics, homecare, military/occupational settings, and research institutions; public programs and hospitals command the largest shares from government-backed universal coverage, with growth in homecare and travel clinics driven by point-of-care convenience and global mobility, emphasizing their role in equitable access and outbreak containment. Geographically, North America holds the largest revenue due to advanced infrastructure and high per-capita spending, Europe follows with stringent regulations, while Asia-Pacific exhibits the fastest growth from population scale, manufacturing hubs (e.g., India, China), and expanding immunization drives collectively propelled by urbanization, aging demographics, and post-COVID vaccine hesitancy mitigation, cementing the market's critical position in global health security.

Market Drivers:-
Global infectious disease prevalence (e.g., influenza, polio, hepatitis) continues to fuel demand for preventive immunization. Seasonal influenza alone affects up to 1 billion people yearly with 3-5 million severe cases, underscoring sustained vaccination needs.

Routine immunization programs particularly for children drive massive volume. Pediatric inactivated vaccine doses reached 2.9 billion in 2023 (65% of total volume), reflecting strong public health program adoption.

Governments and international health bodies (WHO, UNICEF, Gavi) actively fund vaccine programs, ensuring bulk procurement and wide distribution particularly in low- and middle-income regions. Expanded national schedules (e.g., inactivated polio vaccine inclusion in routine schedules across 90+ countries) anchor stable demand.

A growing aging population with higher susceptibility to infections increases uptake of safe vaccine platforms like inactivated formulations that are preferred for vulnerable groups.

Improvements in cell culture, adjuvants, and production methods enhance vaccine potency, stability, and scalability, boosting manufacturer capacity and broadening product pipelines.

-Speak to Our Senior Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/inactivated-vaccines-market?prtk

Market key players:-

1. Serum Institute of India Pvt. Ltd. - 24.8%
Dominates with high-volume, cost-efficient production and large supply contracts for global immunization programs.

2. GSK plc. - 16.7%
Strong R&D capabilities and extensive inactivated vaccine portfolio with a long-standing global immunization presence.

3. Sanofi - 15.3%
Leverages broad distribution networks and established inactivated vaccine offerings with solid public health partnerships.

4. Merck & Co., Inc. - 11.9%
Well-established technologies and regulatory expertise support sustained demand for key inactivated vaccines.

5. Pfizer Inc. - 9.8%
Global manufacturing infrastructure and strong brand integration across vaccine and biopharmaceutical portfolios.

Dominating Regions:

1. North America

North America continues to be a leading contributor, accounting for roughly 44% of the global inactivated vaccines market share in 2025 due to strong healthcare infrastructure, government funding, and high vaccine uptake.

The United States dominates within the region with the majority of dose distribution and pharmaceutical production, driving sustained revenue and adoption.

2. Asia Pacific

Asia Pacific holds a significant share (about 39% of the global market) in 2024-2025, driven by large population bases, expanding immunization programs in China and India, and increased domestic vaccine production.

It is also one of the fastest-growing markets, with proactive government initiatives and expanding healthcare access fuelling growth.

3. Europe

Europe represents around 29% (as per market revenue share estimates) of the inactivated vaccines market in 2025, supported by established healthcare systems and strong public immunization programs.

Germany, France, and the UK are major contributors within this region, maintaining steady demand and distribution volumes.

-Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=inactivated-vaccines-market?prtk

Benefits Of the report-

-Comprehensive Market Overview: Provides insights into the global swarm drones system market, including size, growth trends, and future projections.

-Segmentation Analysis: Detailed breakdown by product type, application, end-user, and region, helping identify high-potential opportunities.

-Competitive Landscape: Highlights key players, recent developments, and strategic initiatives, assisting stakeholders in benchmarking and planning.

-Technological Insights: Explores emerging technologies like AI-driven swarm coordination, autonomous navigation, and counter-drone systems.

-Investment Guidance: Helps investors and businesses evaluate market opportunities, forecast demand, and make informed strategic decisions.

-Regional Insights: Offers a clear understanding of market trends and opportunities across North America, Europe, Asia-Pacific, and other regions.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.